{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:02:45Z","timestamp":1789434165618,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":101,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Department of Biotechnology, Government of India","award":["102\/IFD\/SAN\/3685\/2019\/2020"],"award-info":[{"award-number":["102\/IFD\/SAN\/3685\/2019\/2020"]}]},{"name":"ANRF","award":["CRG\/2022\/003022"],"award-info":[{"award-number":["CRG\/2022\/003022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acute myeloid leukemia (AML) presents significant clinical challenges due to patient heterogeneity and variable treatment responses. Cytogenetic and mutation-based biomarkers dominate current prognostic classifications. However, many patients lack these canonical markers, and most are not therapeutic targets. Gene expression-based biomarkers, despite their clinical potential, remain underexplored. Here, we used transcriptome analyses of primary AML cohorts (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091338) and identified BEN domain-containing protein 4 (\n                    <jats:italic>BEND4<\/jats:italic>\n                    ) as significantly overexpressed in adverse cytogenetic risk. Independent validation (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009350) showed\n                    <jats:italic>BEND4<\/jats:italic>\n                    was significantly overexpressed in relapse and refractory AML patients. High\n                    <jats:italic>BEND4<\/jats:italic>\n                    expression was associated with poor overall survival, increased relapse risk, and was an independent risk factor in AML. Furthermore, in prognostic prediction,\n                    <jats:italic>BEND4<\/jats:italic>\n                    expression outperformed mutation or gene expression-based models and a \u0394ct threshold from RT-qPCR of &lt;12.75 differentiated adverse risk AML patients with 91% sensitivity and 81% specificity. Functionally, BEND4 perturbation modulated chemoresistance to doxorubicin and cytarabine, apoptosis, cell cycle distribution, cellular proliferation and clonogenicity, by altering several oncogenic and inflammation-related molecular pathways. In vivo, BEND4 overexpression promoted leukemogenesis and shortened survival, whereas its suppression decreased tumor burden and improved survival. This study establishes\n                    <jats:italic>BEND4<\/jats:italic>\n                    as a clinically relevant single gene expression-based biomarker and a potential therapeutic target in AML.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01534-7","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:14:25Z","timestamp":1780758865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of BEND4 as a novel single-gene prognostic marker and therapeutic target for adverse AML"],"prefix":"10.1038","volume":"10","author":[{"given":"Archisman","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saket V.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin A.","family":"Dsouza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Salunkhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Chandrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpee","family":"Dutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"1534_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.10","volume":"2","author":"A Khwaja","year":"2016","unstructured":"Khwaja, A. et al. Acute myeloid leukaemia. Nat. Rev. Dis. Primers 2, 16010 (2016).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1534_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H Dohner","year":"2010","unstructured":"Dohner, H. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453\u2013474 (2010).","journal-title":"Blood"},{"key":"1534_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"1534_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00495-3","volume":"11","author":"N Daver","year":"2021","unstructured":"Daver, N., Venugopal, S. & Ravandi, F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 11, 104 (2021).","journal-title":"Blood Cancer J."},{"key":"1534_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22625-y","volume":"12","author":"TR Docking","year":"2021","unstructured":"Docking, T. R. et al. A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia. Nat. Commun. 12, 2474 (2021).","journal-title":"Nat. Commun."},{"key":"1534_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41375-024-02246-2","volume":"38","author":"H Fruchtman","year":"2024","unstructured":"Fruchtman, H., Avigan, Z. M., Waksal, J. A., Brennan, N. & Mascarenhas, J. O. Management of isocitrate dehydrogenase 1\/2 mutated acute myeloid leukemia. Leukemia. 38, 927\u2013935 (2024).","journal-title":"Leukemia."},{"key":"1534_CR8","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/ajh.25214","volume":"93","author":"EH Estey","year":"2018","unstructured":"Estey, E. H. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am. J. Hematol. 93, 1267\u20131291 (2018).","journal-title":"Am. J. Hematol."},{"key":"1534_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1182\/blood.2024024310","volume":"144","author":"J Othman","year":"2024","unstructured":"Othman, J. et al. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML. Blood 144, 714\u2013728 (2024).","journal-title":"Blood"},{"key":"1534_CR10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1200\/JCO.2009.25.1496","volume":"28","author":"H Becker","year":"2010","unstructured":"Becker, H. et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J. Clin. Oncol. 28, 596\u2013604 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1534_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01290-0","volume":"15","author":"MV Shah","year":"2025","unstructured":"Shah, M. V. et al. Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort. Blood Cancer J. 15, 88 (2025).","journal-title":"Blood Cancer J."},{"key":"1534_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01287-9","volume":"15","author":"SC Ni","year":"2025","unstructured":"Ni, S. C. et al. Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations. Blood Cancer J. 15, 97 (2025).","journal-title":"Blood Cancer J."},{"key":"1534_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41375-024-02140-x","volume":"38","author":"JA Georgi","year":"2024","unstructured":"Georgi, J. A. et al. Prognostic impact of CEBPA mutational subgroups in adult AML. Leukemia 38, 281\u2013290 (2024).","journal-title":"Leukemia"},{"key":"1534_CR14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1200\/JCO.22.00715","volume":"41","author":"T Grob","year":"2023","unstructured":"Grob, T. et al. Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia. J. Clin. Oncol. 41, 756\u2013765 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1534_CR15","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1182\/blood-2011-03-340273","volume":"117","author":"M Levis","year":"2011","unstructured":"Levis, M. FLT3\/ITD AML and the law of unintended consequences. Blood. 117, 6987\u20136990 (2011).","journal-title":"Blood."},{"key":"1534_CR16","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/s41375-024-02333-4","volume":"38","author":"A Hernandez-Sanchez","year":"2024","unstructured":"Hernandez-Sanchez, A. et al. Rearrangements involving 11q23.3\/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study. Leukemia. 38, 1929\u20131937 (2024).","journal-title":"Leukemia."},{"key":"1534_CR17","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1182\/blood-2021-154052","volume":"138","author":"AJ Lamble","year":"2021","unstructured":"Lamble, A. J. et al. Crebbp alterations are associated with a poor prognosis in de novo AML. Blood 138, 3451 (2021).","journal-title":"Blood"},{"key":"1534_CR18","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1182\/blood-2024-199037","volume":"144","author":"S Kusurkar","year":"2024","unstructured":"Kusurkar, S. et al. Mutational landscape and factors affecting prognosis in acute myeloid leukemia (AML) with RUNX1::RUNX1T1. Blood 144, 4290 (2024).","journal-title":"Blood"},{"key":"1534_CR19","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony, S., Stahl, M. & Stone, R. M. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 100, 860\u2013891 (2025).","journal-title":"Am. J. Hematol."},{"key":"1534_CR20","doi-asserted-by":"publisher","first-page":"9105","DOI":"10.1182\/blood-2022-164583","volume":"140","author":"A Iat","year":"2022","unstructured":"Iat, A. et al. Comparison of risk stratification tools (ELN-2022, ELN-2017, Lindsley et al., Papaemmanuil et al. and ALFA classifier) in predicting outcomes of patients with acute myeloid leukemia. Blood 140, 9105\u20139106 (2022).","journal-title":"Blood"},{"key":"1534_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7239206","volume":"2019","author":"L Handschuh","year":"2019","unstructured":"Handschuh, L. Not only mutations matter: molecular picture of acute myeloid leukemia emerging from transcriptome studies. J. Oncol. 2019, 7239206 (2019).","journal-title":"J. Oncol."},{"key":"1534_CR22","first-page":"348","volume":"21","author":"S Salunkhe","year":"2020","unstructured":"Salunkhe, S., Chandran, N., Chandrani, P., Dutt, A. & Dutt, S. CytoPred: 7-gene pair metric for AML cytogenetic risk prediction. Brief Bioinform. 21, 348\u2013354 (2020).","journal-title":"Brief Bioinform."},{"key":"1534_CR23","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","volume":"92","author":"D Grimwade","year":"1998","unstructured":"Grimwade, D. et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood 92, 2322\u20132333 (1998).","journal-title":"Blood"},{"key":"1534_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/ejh.13301","volume":"103","author":"YC Chiu","year":"2019","unstructured":"Chiu, Y. C. et al. Integrating resistance functions to predict response to induction chemotherapy in de novo acute myeloid leukemia. Eur. J. Haematol. 103, 417\u2013425 (2019).","journal-title":"Eur. J. Haematol."},{"key":"1534_CR25","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/nm.4125","volume":"22","author":"S Li","year":"2016","unstructured":"Li, S. et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat. Med. 22, 792\u2013799 (2016).","journal-title":"Nat. Med."},{"key":"1534_CR26","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1182\/bloodadvances.2020003727","volume":"5","author":"CJ Walker","year":"2021","unstructured":"Walker, C. J. et al. Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. Blood Adv. 5, 1474\u20131482 (2021).","journal-title":"Blood Adv."},{"key":"1534_CR27","doi-asserted-by":"publisher","first-page":"D1138","DOI":"10.1093\/nar\/gkad993","volume":"52","author":"MH Gislason","year":"2024","unstructured":"Gislason, M. H. et al. BloodSpot 3.0: a database of gene and protein expression data in normal and malignant haematopoiesis. Nucleic Acids Res. 52, D1138\u2013D1142 (2024).","journal-title":"Nucleic Acids Res."},{"key":"1534_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.71","volume":"4","author":"S Weber","year":"2014","unstructured":"Weber, S. et al. BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia. Blood Cancer J. 4, e173 (2014).","journal-title":"Blood Cancer J."},{"key":"1534_CR29","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1200\/JCO.2008.20.5328","volume":"27","author":"KH Metzeler","year":"2009","unstructured":"Metzeler, K. H. et al. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J. Clin. Oncol. 27, 5031\u20135038 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1534_CR30","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/JCO.2008.20.6110","volume":"27","author":"C Langer","year":"2009","unstructured":"Langer, C. et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J. Clin. Oncol. 27, 3198\u20133204 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1534_CR31","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2019-131542","volume":"134","author":"DA Pereira-Martins","year":"2019","unstructured":"Pereira-Martins, D. A. et al. MN1 expression is an indepedent prognostic marker in FLT3-mutated acute myeloid leukemia and is involved in the resistance to FLT3 inhibitors. Blood 134, 1403 (2019).","journal-title":"Blood"},{"key":"1534_CR32","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/leu.2016.11","volume":"30","author":"JM Hones","year":"2016","unstructured":"Hones, J. M. et al. GFI1 as a novel prognostic and therapeutic factor for AML\/MDS. Leukemia 30, 1237\u20131245 (2016).","journal-title":"Leukemia"},{"key":"1534_CR33","unstructured":"DepMap. Available from: https:\/\/depmap.org\/portal."},{"key":"1534_CR34","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u2013D961 (2013).","journal-title":"Nucleic Acids Res."},{"key":"1534_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003088-198815010-00002","volume":"15","author":"PA Speth","year":"1988","unstructured":"Speth, P. A., van Hoesel, Q. G. & Haanen, C. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet. 15, 15\u201331 (1988).","journal-title":"Clin. Pharmacokinet."},{"key":"1534_CR36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2165\/00003088-200241100-00002","volume":"41","author":"A Hamada","year":"2002","unstructured":"Hamada, A., Kawaguchi, T. & Nakano, M. Clinical pharmacokinetics of cytarabine formulations. Clin. Pharmacokinet. 41, 705\u2013718 (2002).","journal-title":"Clin. Pharmacokinet."},{"key":"1534_CR37","doi-asserted-by":"publisher","first-page":"6723","DOI":"10.1158\/1078-0432.CCR-12-2442","volume":"18","author":"JE Karp","year":"2012","unstructured":"Karp, J. E. et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin. Cancer Res. 18, 6723\u20136731 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1534_CR38","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/blood.V90.4.1643","volume":"90","author":"MR Baer","year":"1997","unstructured":"Baer, M. R. et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8; 21)(q22; q22). Blood 90, 1643\u20131648 (1997).","journal-title":"Blood"},{"key":"1534_CR39","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.exphem.2016.07.012","volume":"44","author":"I Laverdiere","year":"2016","unstructured":"Laverdiere, I. et al. Complement cascade gene expression defines novel prognostic subgroups of acute myeloid leukemia. Exp. Hematol. 44, 1039\u201343.e10 (2016).","journal-title":"Exp. Hematol."},{"key":"1534_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45916-6","volume":"15","author":"B Wang","year":"2024","unstructured":"Wang, B. et al. Comprehensive characterization of IFNgamma signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat. Commun. 15, 1821 (2024).","journal-title":"Nat. Commun."},{"key":"1534_CR41","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1182\/blood.V126.23.1348.1348","volume":"126","author":"RO Jacamo","year":"2015","unstructured":"Jacamo, R. O. et al. Effects of CCL2\/CCR2 blockade in acute myeloid leukemia. Blood 126, 1348 (2015).","journal-title":"Blood"},{"key":"1534_CR42","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1172\/JCI68101","volume":"124","author":"Y Kagoya","year":"2014","unstructured":"Kagoya, Y. et al. Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity. J. Clin. Investig. 124, 528\u2013542 (2014).","journal-title":"J. Clin. Investig."},{"key":"1534_CR43","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"Carey","year":"2017","unstructured":"Carey et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 18, 3204\u20133218 (2017).","journal-title":"Cell Rep."},{"key":"1534_CR44","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1080\/10428194.2023.2190432","volume":"64","author":"MK Mustafa Ali","year":"2023","unstructured":"Mustafa Ali, M. K., Williams, M. T., Corley, E. M., AlKaabba, F. & Niyongere, S. Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia. Leuk. Lymphoma 64, 962\u2013971 (2023).","journal-title":"Leuk. Lymphoma"},{"key":"1534_CR45","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1111\/cas.15855","volume":"114","author":"J Lu","year":"2023","unstructured":"Lu, J. et al. Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6\/JAK2\/STAT3 signaling. Cancer Sci. 114, 3287\u20133300 (2023).","journal-title":"Cancer Sci."},{"key":"1534_CR46","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/bioinformatics\/btn007","volume":"24","author":"S Abhiman","year":"2008","unstructured":"Abhiman, S., Iyer, L. M. & Aravind, L. BEN: a novel domain in chromatin factors and DNA viral proteins. Bioinformatics 24, 458\u2013461 (2008).","journal-title":"Bioinformatics"},{"key":"1534_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104734","volume":"299","author":"K Liu","year":"2023","unstructured":"Liu, K. et al. Structural insights into DNA recognition by the BEN domain of the transcription factor BANP. J. Biol. Chem. 299, 104734 (2023).","journal-title":"J. Biol. Chem."},{"key":"1534_CR48","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s13238-021-00884-1","volume":"13","author":"G Shi","year":"2022","unstructured":"Shi, G. et al. Bend family proteins mark chromatin boundaries and synergistically promote early germ cell differentiation. Protein Cell 13, 721\u2013741 (2022).","journal-title":"Protein Cell"},{"key":"1534_CR49","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Cancer","year":"2013","unstructured":"Cancer et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059\u20132074 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR50","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209\u20132221 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2211429119","volume":"119","author":"WY Cheng","year":"2022","unstructured":"Cheng, W. Y. et al. Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 119, e2211429119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1534_CR52","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMoa031046","volume":"350","author":"L Bullinger","year":"2004","unstructured":"Bullinger, L. et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350, 1605\u20131616 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR53","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1182\/blood.V122.21.2619.2619","volume":"122","author":"M Lagergren Lindberg","year":"2013","unstructured":"Lagergren Lindberg, M. et al. Gene expression analyses at time of diagnosis indicate biomarkers predictive of therapeutic response in acute myeloid leukemia. Blood 122, 2619 (2013).","journal-title":"Blood"},{"key":"1534_CR54","first-page":"475","volume":"12","author":"Y Pan","year":"2020","unstructured":"Pan, Y. et al. Gene coexpression network analysis revealed biomarkers correlated with blast cells and survival in acute myeloid leukemia. Mol. Clin. Oncol. 12, 475\u2013484 (2020).","journal-title":"Mol. Clin. Oncol."},{"key":"1534_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13624-1","volume":"11","author":"YR Li","year":"2020","unstructured":"Li, Y. R. et al. Rare copy number variants in over 100,000 European ancestry subjects reveal multiple disease associations. Nat. Commun. 11, 255 (2020).","journal-title":"Nat. Commun."},{"key":"1534_CR56","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1158\/1541-7786.MCR-18-0601","volume":"17","author":"F Chen","year":"2019","unstructured":"Chen, F., Zhang, Y., Varambally, S. & Creighton, C. J. Molecular correlates of metastasis by systematic pan-cancer analysis across the cancer genome atlas. Mol. Cancer Res. 17, 476\u2013487 (2019).","journal-title":"Mol. Cancer Res."},{"key":"1534_CR57","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng, S. W. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433\u2013437 (2016).","journal-title":"Nature"},{"key":"1534_CR58","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood.V122.21.473.473","volume":"122","author":"A Agarwal","year":"2013","unstructured":"Agarwal, A. et al. Critical role of interleukin receptor signaling in acute myeloid leukemia identified using an RNAi functional screen. Blood 122, 473 (2013).","journal-title":"Blood"},{"key":"1534_CR59","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1182\/bloodadvances.2021004962","volume":"6","author":"S Stratmann","year":"2022","unstructured":"Stratmann, S. et al. Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression. Blood Adv. 6, 152\u2013164 (2022).","journal-title":"Blood Adv."},{"key":"1534_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114665","volume":"156","author":"L Zhang","year":"2025","unstructured":"Zhang, L. et al. CD40 promotes AML survival via non-canonical NF-kappaB signaling and aberrant lipid metabolism. Int. Immunopharmacol. 156, 114665 (2025).","journal-title":"Int. Immunopharmacol."},{"key":"1534_CR61","doi-asserted-by":"publisher","first-page":"10074","DOI":"10.1128\/JVI.74.21.10074-10080.2000","volume":"74","author":"U O\u2019Doherty","year":"2000","unstructured":"O\u2019Doherty, U., Swiggard, W. J. & Malim, M. H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol 74, 10074\u201310080 (2000).","journal-title":"J. Virol"},{"key":"1534_CR62","doi-asserted-by":"publisher","first-page":"jcs261931","DOI":"10.1242\/jcs.261931","volume":"137","author":"SV Mishra","year":"2024","unstructured":"Mishra, S. V. et al. DNA-PKcs-mediated transcriptional regulation of TOP2B drives chemoresistance in acute myeloid leukemia. J. Cell Sci 137, jcs261931 (2024).","journal-title":"J. Cell Sci"},{"key":"1534_CR63","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/ijc.31242","volume":"142","author":"S Salunkhe","year":"2018","unstructured":"Salunkhe, S. et al. Inhibition of novel GCN5-ATM axis restricts the onset of acquired drug resistance in leukemia. Int. J. Cancer 142, 2175\u20132185 (2018).","journal-title":"Int. J. Cancer"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01534-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01534-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01534-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:03:36Z","timestamp":1789430616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01534-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1534"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01534-7","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"351"}}